Stifel Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Elanco Animal Health (ELAN)
Elanco Animal Health (NYSE:ELAN Shareholders Incur Further Losses as Stock Declines 6.8% This Week, Taking Three-year Losses to 58%
Elanco Animal Health Is Maintained at Overweight by Barclays
Elanco Animal Health Analyst Ratings
Morgan Stanley Maintains Elanco Animal Health(ELAN.US) With Hold Rating, Maintains Target Price $15
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Raises Target Price to $22
Express News | Elanco Animal Health Shares Are Trading Lower After a William Blair Analyst Highlighted Concerns About Efficacy and Label Warnings With Its Itchy Dogs Dermatology Treatment
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Elanco Animal Health(ELAN.US), With a Forecast Between $15 to $21
Daily short sale tracking: Tesla's short volume increased by 6 million, with a short sale ratio of 11%
Elanco Animal Health (ELAN) Gets a Buy From Barclays
Demystifying Elanco Animal Health: Insights From 4 Analyst Reviews
Elanco Animal Health Gets FDA Approval for Canine Itch Treatment
Express News | Elanco Animal Health Inc: Zenrelia Launch Begins in U.S. With Elanco Now Taking Orders; Product Expected to Ship in Coming Days
Elanco Announces FDA Approval and Launch of Zenrelia (Ilunocitinib Tablets), Offering An Effective, Safe Solution in Canine Dermatology
Express News | Stifel Reiterates Buy on Elanco Animal Health, Maintains $20 Price Target
Sector Update: Health Care Stocks Rise in Afternoon Trading
Elanco Rises on FDA Approval for Zenrelia
Express News | Elanco Animal Health Announces FDA Approval For Zenrelia, For The Control Of Pruritus Associated With Allergic Dermatitis And Control Of Atopic Dermatitis In Dogs At Least 12 Months Of Age